A Single-Center, Open-Label Phase 2a Clinical Trial to Evaluate the Safety and Efficacy of GR-MD-02 for the Treatment of Patients With Moderate to Severe Plaque Psoriasis
Phase of Trial: Phase II
Latest Information Update: 04 Aug 2017
At a glance
- Drugs GR MD 02 (Primary)
- Indications Plaque psoriasis
- Focus Proof of concept; Therapeutic Use
- Sponsors Galectin Therapeutics
- 31 Jul 2017 Planned End Date changed from 1 Mar 2017 to 1 Mar 2018.
- 31 Jul 2017 Planned primary completion date changed from 1 Mar 2017 to 1 Mar 2018.
- 06 Mar 2017 Results published in a Galectin Therapeutics media release.